ArticleEuropean journal of pharmacology2009
An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice.
Article in European journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Integrin α4β7: Pathogenic Roles in Metabolic and Inflammatory Diseases and Translational Therapeutics.Journal of inflammation research · 2026Review
- Evaluation of VLA-4 (Integrin α4β1) as a Shared Target for Radiopharmaceutical Therapy across Solid Tumors.Molecular cancer therapeutics · 2025Article
- The immunoregulatory role of integrins in pulmonary diseases.Frontiers in immunology · 2025Review
- Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.EJNMMI research · 2023Article
- Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- DS-70, a novel and potent αBritish journal of pharmacology · 2018Article
- Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.Advances in cancer research · 2015Review
- Role of integrin alpha4 in drug resistance of leukemia.Frontiers in oncology · 2014Review
- Dual oxidase regulates neutrophil recruitment in allergic airways.Free radical biology & medicine · 2013Article
- Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation.PloS one · 2013Article
- Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues.Frontiers in immunology · 2013Article
- Treatment of allergic asthma: modulation of Th2 cells and their responses.Respiratory research · 2011Review
- PPARγ agonist rosiglitazone prevents perinatal nicotine exposure-induced asthma in rat offspring.American journal of physiology. Lung cellular and molecular physiology · 2011Article
- Protective B cell responses to flu--no fluke!Journal of immunology (Baltimore, Md. : 1950) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Inhibition of the alpha4 subunit of both the alpha4beta1 and alpha4beta7 integrins has shown promise in decreasing airway inflammation and airway hyperresponsiveness in various animal models. We hypothesized that a novel, high-affinity alpha4beta1 antagonist (LLP2A) would decrease the migration of eosinophils to the lung and ameliorate the airway hyperresponsiveness in a mouse model of ovalbumin-induced airway inflammation. To test this hypothesis, we administered LLP2A, or scrambled LLP2A (a negative control), prior to exposure of sensitized BALB/c mice to ovalbumin aerosol. We can partially prevent, or reverse, the airway inflammatory response, but not airways hyperresponsiveness, by treatment of mice with LLP2A, a synthetic peptidomimetic alpha4beta1 antagonist. Specifically engineered, PEGylated (PEG) formulations of this antagonist further reduce the airway inflammatory response to ovalbumin, presumably by improving the circulating half-life of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.